Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11859589 | 1.00 | HCAR2 (0.54) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL2079639 | 1.00 | HCAR2 (0.54) | HCAR2TSHRTP53EGLN1EGLN3 | |
| Acrylic Acid SCHEMBL28914099 | 0.92 | HCAR2 (0.47) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL9384923 | 0.91 | HCAR2 (0.39) | HCAR2TSHRTP53ALDH1A1KEAP1 | |
| SCHEMBL746755 | 0.91 | HCAR2 (0.39) | HCAR2TSHRTP53ALDH1A1KEAP1 | |
| Methacrylic Acid SCHEMBL28568084 | 0.89 | HCAR2 (0.44) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL8460434 | 0.89 | HCAR2 (0.38) | HCAR2TSHRTP53ALDH1A1KEAP1 | |
| SCHEMBL16681177 | 0.89 | HCAR2 (0.38) | HCAR2TSHRTP53ALDH1A1KEAP1 | |
| SCHEMBL14157639 | 0.89 | HCAR2 (0.38) | HCAR2TSHRTP53ALDH1A1KEAP1 | |
| Acrylic Acid Methyl Ester SCHEMBL28567664 | 0.86 | HCAR2 (0.50) | HCAR2TSHRALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851108-B1 | BORATE-BASED DRUG AND USE THEREOF | CHENGDU ORIGIN BIOTECHNOLOGY LTD COMPANY (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3851108-A1 | BORATE-BASED DRUG AND USE THEREOF | Chengdu Origin Biotechnology Limited Company (CN) | 2021-07-21 | — | — | EP | disclosed |
| EP-2271656-A1 | 2'-O,3'-N-BRIDGED MACROLIDES | GLAXO GROUP LIMITED (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130189-A1 | 2'-O,3'-N-BRIDGED MACROLIDES | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-10-29 | — | — | WO | disclosed |
| CN-101448505-A | PI3 kinase antagonists | UNIV CALIFORNIA (US) | 2009-06-03 | — | — | CN | disclosed |
| CN-1082040-A | Indoles | PFIZER RES & DEV (IE) | 1994-02-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | PSMB11, PSMB1, PSMB3 | HCAR2 2514/4885TSHR 967/4885TP53 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.